CDKN2B

Across TCGA pan-cancer cohorts, CDKN2B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDKN2B data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDKN2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDKN2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where CDKN2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	1.000	0.645	.014	2	view →
PDAC	OS	Tertile	II,III,IV	0.648	0.405	.049	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDKN2B–LUAD (OS)

Open the LUAD breakdown →